Payment overview · 2025
General Payments
$73.04
4 reported records · 4 companies
Healthcare provider profile · identity verified
Luis Thormer Chastain, MD
Allopathic & Osteopathic Physicians|Family Medicine · GEORGETOWN, SC · NPI 1467477661
Verified facts
What the public records show
CMS Open Payments records show Luis Thormer Chastain, MD received $73.04 in general payments during 2025 across 4 reported records.
Astellas Pharma US Inc accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.73 | 31.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.98 | 26.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.10 | 23.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.23 | 19.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $73.04 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
330 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 899 | 221 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 639 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 487 | 138 |
| Gabapentin | Gabapentin | 443 | 123 |
| Losartan Potassium | Losartan Potassium | 426 | 102 |
| Omeprazole | Omeprazole | 399 | 98 |
| Duloxetine Hcl | Duloxetine Hcl | 398 | 108 |
| Valsartan | Valsartan | 393 | 93 |
| Metformin Hcl | Metformin Hcl | 387 | 101 |
| Chlorthalidone | Chlorthalidone | 374 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 93 |
| Eliquis | Apixaban | 330 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 321 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 298 | 139 |
| Spironolactone | Spironolactone | 281 | 63 |
| Trazodone Hcl | Trazodone Hcl | 277 | 81 |
| Sertraline Hcl | Sertraline Hcl | 254 | 62 |
| Furosemide | Furosemide | 248 | 63 |
| Lisinopril | Lisinopril | 245 | 64 |
| Famotidine | Famotidine | 232 | 66 |
| Potassium Chloride | Potassium Chloride | 223 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 89 |
| Glipizide | Glipizide | 180 | 49 |
| Lovastatin | Lovastatin | 178 | 51 |
| Jardiance | Empagliflozin | 168 | 29 |
| Allopurinol | Allopurinol | 164 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 37 |
| Carvedilol | Carvedilol | 148 | 35 |
| Tramadol Hcl | Tramadol Hcl | 142 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 28 |
| Montelukast Sodium | Montelukast Sodium | 129 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 32 |
| Mirtazapine | Mirtazapine | 116 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 29 |
| Metformin Hcl Er | Metformin Hcl | 111 | 31 |
| Nifedipine Er | Nifedipine | 104 | 27 |
| Simvastatin | Simvastatin | 101 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 28 |
| Indapamide | Indapamide | 98 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 26 |
| Prednisone | Prednisone | 97 | 76 |
| Bupropion Xl | Bupropion Hcl | 93 | 24 |
| Buspirone Hcl | Buspirone Hcl | 93 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 76 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 47 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 21 |
| Donepezil Hcl | Donepezil Hcl | 82 | 23 |
| Meloxicam | Meloxicam | 76 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 19 |
| Trulicity | Dulaglutide | 72 | 11 |
| Colchicine | Colchicine | 70 | 27 |
| Doxepin Hcl | Doxepin Hcl | 69 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 13 |
| Alendronate Sodium | Alendronate Sodium | 59 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 17 |
| Myrbetriq | Mirabegron | 56 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Meclizine Hcl | Meclizine Hcl | 52 | 28 |
| Ezetimibe | Ezetimibe | 51 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Torsemide | Torsemide | 49 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 16 |
| Irbesartan | Irbesartan | 48 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 13 |
| Xarelto | Rivaroxaban | 46 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 22 |
| Lorazepam | Lorazepam | 43 | 12 |
| Nystatin | Nystatin | 42 | 18 |
| Ozempic | Semaglutide | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 14 |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | 11 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Eplerenone | Eplerenone | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Sulindac | Sulindac | 21 | 16 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73.04 · 4 records | Astellas Pharma US Inc | ABRYSVO, COMIRNATY, Ozempic, PREVNAR 20, Rybelsus, VRAYLAR, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error